Experienced in Membranous Nephropathy

Stephane Burtey

Marseille, FR 
Experienced in Membranous Nephropathy
Marseille, FR 
OverviewLocationsClinical Research

Overview

Stephane Burtey practices in Marseille, France. Ms. Burtey is rated as an Experienced expert by MediFind in the treatment of Membranous Nephropathy. Her top areas of expertise are Autosomal Dominant Tubulointerstitial Kidney Disease, Glomerulonephritis, Interstitial Nephritis, Kidney Transplant, and Thrombectomy.

Her clinical research consists of co-authoring 148 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 1 clinical trial in the study of Membranous Nephropathy.

Gender
Female

Locations

Marseille, France
Other Locations
Thionville, France
Aix-en-provence, 13005, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial
Enrollment Status: Terminated
Publish Date: August 26, 2025
Intervention Type: Drug
Study Drug: L-Carnitine
Study Phase: Phase 3
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary FSGS
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Drug
Study Drugs: Sparsentan, Irbesartan
Study Phase: Phase 3
Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA
Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Procedure
Study Phase: Not Applicable
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)
Enrollment Status: Completed
Publish Date: December 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

148 Total Publications

A guide to uraemic toxicity.
A guide to uraemic toxicity.
Journal: Nature reviews. Nephrology
Published: August 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Burtey's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile